Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.

[1]  Joseph M. Volpe,et al.  Five Antiretroviral Drug Class–Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection , 2015, Journal of the International Association of Providers of AIDS Care.

[2]  Jerome H. Kim,et al.  Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis , 2015, PLoS medicine.

[3]  P. Cahn,et al.  Raltegravir: a new antiretroviral class for salvage therapy , 2007, The Lancet.

[4]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[5]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[6]  M. Lederman,et al.  MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study , 2003, Journal of acquired immune deficiency syndromes.

[7]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[8]  P. Pham,et al.  Expanded access drug profile: raltegravir (RAL, MK-0518). , 2007, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

[9]  M. Egger,et al.  Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. , 2007, Antiviral therapy.